119 results on '"Yamada, Y."'
Search Results
2. CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 ‘gene desert’, serve as important prognostic biomarkers in colorectal cancer
3. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
4. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
5. 723P Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial
6. 952P Comprehensive analysis of cytokines and PDL1 before and after administration of atezolizumab and bevasizumab in patients with HCC
7. 174P Pulmonary tuft cell-like cancers across different histotypes share molecular features with potentially druggable vulnerabilities
8. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
9. 1140P Validation of a deep learning model for the classification of lung cancer in a large cohort of biopsied samples
10. 1662P Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay
11. O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results
12. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
13. Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
14. Clinical biopsychosocial risk factors for depression in lung cancer patients: a comprehensive analysis using data from the Lung Cancer Database Project
15. 5-FU INDUCED ENCEPHALOPATHY DURING 5-FU CONTAINING REGIMEN FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
16. SRPX2 IS A NOVEL CHONDROITIN SULFATE PROTEOGLYCAN THAT IS OVEREXPRESSED IN GASTROINTESTINAL CANCER
17. AMPLIFICATION OF OCT4-PSEUDOGENE POU5F1B IS A POOR PROGNOSTIC FACTOR IN GASTRIC CANCER
18. A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
19. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer
20. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer*
21. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
22. The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
23. Computed tomography features of resected lung adenocarcinomas with spread through air spaces
24. A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma
25. 512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
26. A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
27. Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer
28. 799P - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
29. 250P Different PSA response with abiraterone acetate between mCRPC patients treated in clinical trial and clinical practice
30. 1814P - Computed tomography features of resected lung adenocarcinomas with spread through air spaces
31. 1357P - A positive correlation between the EZH2 and PD-L1 expression in patients with resected lung adenocarcinoma
32. LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
33. P-136 De novo malignancy after living donor liver transplantation
34. 663P - Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer
35. 257P - A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies
36. Amrubicin Monotherapy in Patients with Platinum-Refractory Metastatic Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma of the Gastrointestinal Tract
37. A Phase Ii Study of Nedaplatin and Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer
38. Impacts of Progression Type on Overall Survival in Advanced Gastric Cancer: Randomized Piii Study of S-1 + Oxaliplatin Vs. S-1 + Cisplatin
39. Phase || Study of Pemetrexed + Carboplatin + Bevacizumab As First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer with Egfr Mutation, Result of Induction Therapy: Central Japan Lung Study Group (Cjlsg) 0910 Trial
40. Value of KRAS, BRAF and PIK3CA Mutations and Benefits from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
41. The Risk Factors for Bleomycin Pulmonary Toxicity for Hodgkin Lymphoma and Germ-Cell Tumor: A Single-Center Analysis
42. Forty-One Cases of Metastases From Gastric Cancer to the Central Nerve System: Experience at a Single Institution
43. Frequency of HPV Infection and EGFR, MAPK Pathway, and PIK3CA Mutation Profiles in SCC of the Cervical Esophagus
44. Safety and Efficacy of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer: A Subgroup Analysis of the Phase III Correct Trial
45. A Phase I and Dose-Finding Study of Lenvatinib (E7080) in Japanese Patients with Advanced Solid Tumors
46. A Phase 1 Study of Cabozantinib in Japanese Patients with Advanced Solid Tumors: Anti-Tumor Activity in NSCLC and GIST
47. A Retrospective Comparison Study of Docetaxel and Paclitaxel for Previously Treated Chemotherapy for Esophageal Cancer
48. Phase I Study of LY2523355, an EG5 Inhibitor, in Japanese Patients with Advanced Solid Tumors
49. Activin-A Directly Inhibits Vascular Endothelial Cell Growth VIA TGF-b-Dependent Signal Pathway
50. Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of RO5126766, a First-in-Class Dual Raf/Mek Inhibitor, in Japanese Patients with Advanced Solid Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.